Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Start-ups

Kelonia launches with $50 million to simplify gene therapy

by Michael McCoy
April 30, 2022 | A version of this story appeared in Volume 100, Issue 15

 

Kelonia Therapeutics has launched with $50 million in series A funding to develop genetic medicines using what it calls off-the-shelf in vivo gene delivery. Kelonia says existing gene therapies are complex, costly, and limited by complicated treatments and dose-limiting toxicities. It plans to use lentiviral vector-like particles discovered in Michael Birnbaum’s lab at the Massachusetts Institute of Technology to deliver genetic payloads for a broad range of diseases.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.